Please try another search
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
Name | Age | Since | Title |
---|---|---|---|
Jae Soo Shin | - | 2018 | Member of Advisory Board |
Hyun Soo Lee | - | 2018 | Member of Advisory Board |
Sang Goo Kim | 57 | 2015 | Independent Director |
Heon Ju Lee | - | 2018 | Member of Advisory Board |
Konstantin Lichtenwald | 39 | 2018 | CFO, Corporate Secretary & Director |
Yee Sing Cheng | 42 | 2023 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review